Clinical trials: Sertraline
Depressive Disorder, Major
A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.
This study was designed to determine if the novel combination of the SSRI, sertraline, and the NRI reboxetine will increase antidepressant efficacy without sacrificing the favorable safety profile of SSRIs.
- Trial name
- NCT00636246
- Testing
- sertraline/[S,S]-reboxetine, sertraline, [S,S]-reboxetine monotherapy
- Where
- 17 sites in Estonia, Russia
- Volunteers
- 510 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depressive Disorder, Major
Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
A six week, fixed dose, double-blind, double-dummy, placebo, and active controlled, multicentre trial to evaluate the safety and efficacy of CP-316,311 in outpatients with major depressive disorder.
- Trial name
- NCT00143091
- Testing
- CP-316,311, Sertraline
- Where
- 10 sites in United States, Russia and 1 more
- Volunteers
- 200 people
- Sponsor
- Pfizer
Healthy
Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg
The objective of this study was to investigate the bioequivalence of Mylan's sertraline hydrochloride 100 mg tablets to Pfizer's Zoloft® 100 mg tablets following a single, oral 100 mg (1 x 100 mg) dose administered under fasting…
- Trial name
- NCT00650325
- Testing
- Sertraline Hydrochloride Tablets 100 mg, Zoloft® Tablets 100 mg
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine…
- Trial name
- TRANSFORM-2 (NCT02418585)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 48 sites in United States, Czechia and 3 more
- Volunteers
- 236 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
Sertraline Hydrochloride 100 mg Tablets, Fed
The objective of this study is to compare the rate and extent of absorption of sertraline hydrochloride 100 mg tablets (test) versus Zoloft® (reference) administered as 1 x 100 mg tablet under fed conditions.
- Trial name
- NCT00836667
- Testing
- Zoloft® 100 mg Tablets, Sertraline hydrochloride 100 mg Tablets
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
Food Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg
The objective of this study was to investigate the bioequivalence of Mylan's sertraline hydrochloride 100 mg tablets to Pfizer's Zoloft® 100 mg tablets following a single, oral 100 mg (1 x 100 mg) dose administration under fed…
- Trial name
- NCT00648856
- Testing
- Sertraline Hydrochloride Tablets 100 mg, Zoloft® Tablets 100 mg
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Major Depressive Disorder
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study
This study is an optional continuation of previous short-term adult major depressive disorder (MDD) augmentation studies. Patients may only take part in this long-term, open-label research study if they completed a previous…
- Trial name
- NCT01436175
- Testing
- SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
- Where
- 212 sites in United States, Canada and 12 more
- Volunteers
- 1,570 people
- Sponsor
- Shire
Obesity
Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
The hypothesis of this study is that up to 150 mg of sertraline and up to 3 mg of telenzepine will be safe, tolerable, and have the effect of suppressing appetite, when taken in combination daily by mouth by healthy, overweight…
- Trial name
- NCT01155531
- Testing
- Sertraline plus Telenzepine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theracos
Major Depression
Cimicoxib for the Treatment of Major Depression (SECIM)
This multicenter study aims to investigate the safety and efficacy of cimicoxib, a selective COX-2 inhibitor, in combination with sertraline compared to sertraline combined with placebo in patients with major depression.
- Trial name
- NCT00510822
- Testing
- Cimicoxib
- Where
- 25 sites in Austria, Czechia and 1 more
- Volunteers
- 169 people
- Sponsor
- Affectis Pharmaceuticals AG
Depressive Disorder, Depression
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Orion (NCT01360866)
- Testing
- OPC-34712, Escitalopram, Fluoxetine
- Where
- 142 sites in United States, Canada and 9 more
- Volunteers
- 2,944 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram [mg] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an…
- Trial name
- NCT03321526
- Testing
- JNJ-42847922, Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI)
- Where
- 50 sites in United States
- Volunteers
- 107 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect…
- Trial name
- NCT02279953
- Testing
- Vortioxetine 10-20 mg, SSRI
- Where
- 17 sites in Estonia, Finland and 3 more
- Volunteers
- 151 people
- Sponsor
- H. Lundbeck A/S
Healthy Volunteers
A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg/Sertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects
The purpose of this study is to investigate the bioequivalence of ASC-01 Placebo and sertraline Tablet in Japanese healthy male subjects.
- Trial name
- NCT02088697
- Testing
- ASC-01
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depression Disorder
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
The purpose of this study is to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in an elderly population with major depressive disorder and an inadequate response to antidepressant treatment
- Trial name
- NCT02400346
- Testing
- Adjunct brexpiprazole, ADT
- Where
- 34 sites in United States, Estonia and 3 more
- Volunteers
- 132 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
To assess the comparative efficacy of sertraline versus venlafaxine XR on measures of quality of life.
- Trial name
- NCT00644982
- Testing
- sertraline, venlafaxine XR
- Where
- 14 sites in Australia, Turkey (Türkiye)
- Volunteers
- 163 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Post-traumatic Stress Disorder, PTSD
Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)
To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine (PAR) or sertraline (SER) on PTSD symptoms.
- Trial name
- NCT01987960
- Testing
- Brexpiprazole
- Where
- 59 sites in United States, Estonia and 7 more
- Volunteers
- 417 people
- Sponsor
- H. Lundbeck A/S
Healthy
Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fasting Conditions
The purpose of this study was to evaluate the relative bioavailability of the test formulation of sertraline 100 mg tablets with an already marketed reference formulation Zoloft® 100 mg tablets (Pfizer), under fasted conditions…
- Trial name
- NCT00779350
- Testing
- sertraline 100 mg tablets
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited